Research Topics
| Howard FillitSummaryAffiliation: Institute for the Study of Aging Country: USA Publications
| Collaborators
|
Detail Information
Publications
Polypharmacy management in Medicare managed care: changes in prescribing by primary care physicians resulting from a program promoting medication reviewsH M Fillit
Institute for the Study of Aging, New York, NY 10153, USA
Am J Manag Care 5:587-94. 1999..To examine the effects of medication reviews by primary care physicians on prescriptions written for elderly members of a Medicare managed care organization who were at risk for polypharmacy...
The costs of vascular dementia: a comparison with Alzheimer's diseaseHoward Fillit
Institute for the Study of Aging, New York, NY 10153, USA
J Neurol Sci 203:35-9. 2002..To estimate the costs of Medicare patients with vascular dementia (VaD). To compare the costs of VaD to Alzheimer's disease (AD) and controls without dementia...
Optimizing coding and reimbursement to improve management of Alzheimer's disease and related dementiasHoward Fillit
Institute for the Study of Aging, New York, New York 10153, USA
J Am Geriatr Soc 50:1871-8. 2002....
The role of hormone replacement therapy in the prevention of Alzheimer diseaseHoward M Fillit
The Institute for the Study of Aging, Inc, New York, NY 10153, USA
Arch Intern Med 162:1934-42. 2002..Ongoing clinical studies may help to determine the role of estrogen in the cognitive function of postmenopausal women and in the prevention of AD...
Achieving and maintaining cognitive vitality with agingHoward M Fillit
Institute for the Study of Aging, Inc, New York, NY 10153, USA
Mayo Clin Proc 77:681-96. 2002..The data presented in this review should interest physicians who provide preventive care management to middle-aged and older individuals who seek to maintain cognitive vitality with aging...
Barriers to drug discovery and development for Alzheimer diseaseHoward M Fillit
The Institute for the Study of Aging, Inc, New York, New York, USA
Alzheimer Dis Assoc Disord 16:S1-8. 2002..The identified barriers and potential solutions will be discussed here and in the accompanying articles in more detail...
Impact of donepezil on caregiving burden for patients with Alzheimer's diseaseH M Fillit
Institute for the Study of Aging, New York, New York 10153, USA
Int Psychogeriatr 12:389-401. 2000..In conclusion, better management of AD symptoms through donepezil treatment may reduce the burden of caregiving, providing physicians with a pharmacologic approach to improving quality of life for AD patients and their families...
Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control studyShaoli Lu
Institute for the Study of Aging, New York, New York 10019, USA
Am J Geriatr Pharmacother 3:92-102. 2005..However, there are limited studies examining the impact on health care costs of cholinesterase inhibitors prescribed in routine clinical practice...
Economics of dementia and pharmacoeconomics of dementia therapyHoward Fillit
Institute for the Study of Aging, Inc, New York, New York 10019, USA
Am J Geriatr Pharmacother 3:39-49. 2005..In 1997, the cost of managing patients with Alzheimer's disease and other dementias was estimated at US dollar 100 billion. Direct medical costs are compounded by indirect costs of care, including unpaid care and loss of earnings...
Cardiovascular risk factors and dementiaHoward Fillit
Institute for the Study of Aging and the Alzheimer s Drug Discovery Foundation, New York, New York 10019, USA
Am J Geriatr Pharmacother 6:100-18. 2008..Evidence is accumulating to suggest that cardiovascular disease (CVD) risk factors may be instrumental in the development of dementia...
Patterns of healthcare utilization and costs for vascular dementia in a community-dwelling populationJerrold Hill
Institute for the Study of Aging, New York, NY 10019, USA
J Alzheimers Dis 8:43-50. 2005..While vascular dementia (VaD) is the second most prevalent dementia diagnosis, little is known about healthcare use and costs for VaD...
The economic benefits of acetylcholinesterase inhibitors for patients with Alzheimer disease and associated dementiasHoward Fillit
Institute for the Study of Aging, Inc, New York, NY 10453, USA
Alzheimer Dis Assoc Disord 18:S24-9. 2004....
Validation of a brief screen for cognitive impairment (BSCI) administered by telephone for use in the medicare populationJerrold Hill
Institute for the Study of Aging, New York, New York 10019, USA
Dis Manag 8:223-34. 2005..The use of brief screening instruments for dementia, such as the one validated here, will be increasingly important for the effective management of dementia and other chronic diseases where dementia is a coexisting condition...
Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapyHoward Fillit
Institute for the Study of Aging, New York, USA
Fam Med 34:528-35. 2002..This study analyzed the relationship between co-morbid conditions and health care utilization and costs for patients with AD and estimated costs by stage of disease and receipt of pharmacotherapy...
The effect of donepezil therapy on health costs in a Medicare managed care planJerrold W Hill
Institute for the Study for Aging, New York City, USA
Manag Care Interface 15:63-70. 2002..By improving cognitive and daily functioning, donepezil may lower costs by improving medical management...
Biomarkers of aging: from primitive organisms to humansRobert N Butler
International Longevity Center USA, 60 E 86th St, New York, NY 10028, USA
J Gerontol A Biol Sci Med Sci 59:B560-7. 2004..Finally, and significantly, it is difficult to obtain funding for this research...
Neurogenesis as a therapeutic strategy for cognitive aging and Alzheimer's diseaseGunnar Gouras
Dept. of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, NY, USA
Curr Alzheimer Res 3:3. 2006
Cardiovascular disease risk factors and cognitive impairmentDavid T Nash
Upstate Medical University, Syracuse Preventive Cardiology, Syracuse, New York, USA
Am J Cardiol 97:1262-5. 2006..Antioxidants, fatty acids, and micronutrients may have a role, and diets rich in fruits and vegetables and other dietary approaches may improve the outlook for patients considered at risk for cognitive impairment...
Memantine discontinuation and the health status of nursing home residents with Alzheimer's diseaseHoward Fillit
Brookdale Department of Geriatrics and Adult Development, The Mount Sinai School of Medicine, New York, NY, USA
J Am Med Dir Assoc 11:636-644. 2010..To estimate the effect of memantine discontinuation for a nonmedical reason (eg, formulary restriction or family decision) on the health status of nursing home (NH) residents with Alzheimer's disease (AD)...
Intravenous immunoglobulins for Alzheimer's diseaseHoward Fillit
Institute for the Study of Aging, New York, NY, USA
Lancet Neurol 3:704. 2004
The frailty identity crisisHoward Fillit
Institute for the Study of Aging, Mopunt Sinai Medical Center, New York, New York, USA
J Am Geriatr Soc 57:348-52. 2009..Early detection, management, and counseling of individuals experiencing the frailty identity crisis has implications for the health and quality of life of frail individuals, their loved ones and caregivers, and society...
Drug discovery and the prevention of Alzheimer's diseaseHoward Fillit
Executive Director, The Alzheimer s Drug Discovery Foundation, New York, NY, USA
Alzheimers Dement 4:S26-8. 2008..Ultimately, the development of truly effective disease-modifying drugs through accelerated drug discovery is the only real pathway to primary prevention...
Recommendations for best practices in the treatment of Alzheimer's disease in managed careHoward M Fillit
Alzheimer s Drug Discovery Foundation and Institute for the Study of Aging New York, New York 10019, USA
Am J Geriatr Pharmacother 4:S9-S24; quiz S25-S28. 2006..However, these clinical guidelines have not been updated in the past few years...
Strategies for drug discovery for cognitive aging and Alzheimer's diseaseHoward M Fillit
The Institute for the Study of Aging, New York, NY, USA
J Mol Neurosci 19:1-3. 2002
Practicality of a computerized system for cognitive assessment in the elderlyHoward M Fillit
Institute for the Study of Aging, Inc, New York, NY, USA
Alzheimers Dement 4:14-21. 2008..This study evaluated its feasibility for assessment of the elderly...
Drug discovery for Alzheimer's disease: filling the pipelineAntony R Horton
Curr Alzheimer Res 4:501-2. 2007
Advancing drug discovery for Alzheimer's diseaseHoward M Fillit
The Institute for the Study of Aging, 1414 Avenue of the Americas, Suite 1502, New York, NY, USA
Curr Alzheimer Res 2:105-7. 2005
Tau and Alzheimer's disease: the long road to anti-tangle therapeuticsHoward M Fillit
The Institute for the Study of Aging, New York, NY, USA
J Mol Neurosci 19:249-50. 2002
Autoimmune markers in HIV-associated dementiaSteven E Schutzer
Department of Medicine, UMDNJ New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, USA
J Neuroimmunol 138:156-61. 2003..Reactivity against control tissue was negative. Though the etiopathogenetic relation of these antibrain antibodies remains to be delineated, the data suggest that they may be a marker of HAD...
Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer's diseaseLorenzo M Refolo
Institute for the Study of Aging, New York, NY 10153, USA
J Mol Neurosci 23:151-5. 2004..Putative pathological functions, or risk-factor activities, of apoE4 include its role in beta-amyloid deposition, neurofibrillary tangle formation, synaptic loss, lipid dysfunction, neuroinflammation, and oxidative stress...
Drug discovery for Alzheimer's disease: the end of the beginningLorenzo M Refolo
The Institute for the Study of Aging, New York, NY, USA
J Mol Neurosci 24:1-8. 2004
